Subhechcha Ganguly 
According to the Hyderabad-based company, the vaccine, iNCOVACC (BBV154), is now offered on CoWin and is priced at Rs 800 for private markets and Rs 325 for sales to the federal and state governments. The nation will soon receive a booster dosage of the first intranasal vaccination for Covid-19 in the world, developed by the pharmaceutical company Bharat Biotech. According to the Hyderabad-based company, the vaccine, iNCOVACC (BBV154), is now offered on CoWin and is priced at Rs 800 for private markets and Rs 325 for sales to the federal and state governments.
The Central Drugs Standard Control Organization (CDSCO) granted Bharat Biotech permission to deploy heterologous booster dosages of iNCOVACC last month. It is an adenovirus-vectored recombinant vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein. The company said that this vaccine candidate underwent successful evaluation in phases I, II, and III of clinical trials. Nasal drops can be used to give intranasally using iNCOVACC, which has been specially prepared to do so. It was mentioned that the nasal delivery method was created and developed to be affordable in low- and middle-income nations.
According to the vaccine manufacturer, iNCOVACC’s production technology has the dual advantages of speeding up the development of variant-specific vaccines and facilitating simple nasal delivery that permits mass immunisation to guard against worrying developing variants. iNCOVACC was tested in clinical studies as a primary dosage schedule and as a heterologous booster dose for patients who had already received two doses of the two COVID vaccines that are often used in India. In collaboration with Washington University in St. Louis, which created the recombinant adenoviral vectored construct and tested its efficiency in preclinical research, iNCOVACC was created.
